Specific increase in potency via structure-based design of a TCR

Area of Science:

• Immunology
• Cancer Therapy
• Structural Biology

Background:

• Adoptive immunotherapy using antigen-specific T lymphocytes shows promise for cancer treatment.
• Tumor antigens are often "self" proteins, posing challenges for immunotherapy design.
• Enhancing T cell activation potency is crucial for improving clinical responses in adoptive immunotherapy.

Purpose of the Study:

• To utilize structure-based design to engineer T cell receptors (TCRs) with enhanced binding affinity for tumor antigens.
• To investigate the impact of TCR point mutations on T cell activation potency and specificity.
• To explore the potential of affinity-optimized TCRs in cancer immunotherapy, specifically for melanoma.

Main Methods:

• Employed structure-based design to predict point mutations in a T cell receptor (DMF5).
• Focused on enhancing binding affinity for the Mart-1 (27L)-HLA-A2 peptide-MHC complex.
• Analyzed the effects of mutated TCRs on T cell activation potency and cross-reactivity with related antigens.

Main Results:

• Mutated TCRs demonstrated significantly improved T cell activation potency against the target tumor antigen.
• The engineered TCRs maintained a high degree of specificity for the intended Mart-1 (27L) epitope.
• Structure-based design successfully yielded affinity-optimized TCRs with enhanced antitumor capabilities.

Conclusions:

• Structure-based design is a viable strategy for enhancing TCR affinity and potency in adoptive immunotherapy.
• Engineered TCRs show potential for improved melanoma treatment by increasing T cell efficacy against tumor cells.
• This approach may help mitigate adverse autoimmunity effects by ensuring high specificity for tumor antigens.